ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Search through all presentations

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...cancer-mCRC-refractory-to-standard-therapies

AimTAS-102 is a combination of a novel oral nucleoside, trifluridine (FTD) with the thymidine phosphorylase inhibitor, tipiracil hydrochloride (TPI), which prevents the degradation of FTD, enabling sustained and effective FTD levels.

Date: 27 Sep 2014
Presenter: Eric Van Cutsem
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-2014/Complications-arising-with-compliances

Date: 27 Sep 2014
Presenter: Andrea Antonuzzo
Resources: Presentation, Webcast
Topics: Complications of Treatment, Palliative and Supportive Care

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Metabolic-disorders

Date: 27 Sep 2014
Presenter: Viktor Grünwald
Resources: Presentation, Webcast
Topic: Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...014/Organ-toxicities-from-targeted-therapies

Date: 27 Sep 2014
Presenter: Paolo Bossi
Resources: Presentation, Webcast
Topics: Complications of Treatment, Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...Fertility-preservation-in-the-cancer-patient

Date: 27 Sep 2014
Presenter: Hamish Wallace
Resources: Presentation, Webcast
Topic: Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...s-who-were-antenatal-exposed-to-radiotherapy

AimThe use of radiation in medical diagnostics and treatment is standard of care. Apart from deductions from atom bomb and nuclear plant disaster survivors, there are scarce data on the long-term outcome...

Date: 27 Sep 2014
Presenter: Frédéric Amant
Resources: Abstract
Topics: Complications of Treatment, Supportive Care, Cancer in Special Situations, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ereditary-breast-and-ovarian-cancer-syndrome

AimDespite evidence supporting the benefits of risk reduction, protocols for early detection and prevention among women from families affected by hereditary breast and ovarian cancer (HBOC) are not yet...

Date: 27 Sep 2014
Presenter: Allison Werner-Lin
Resources: Abstract
Topics: Ovarian Cancer, Cancer in Young Adults, Supportive Care, Breast Cancer, Familial Cancer

http://oncologypro.esmo.org/Meeting-Resourc...cer-patients-receiving-bone-modifying-agents

AimBone-modifying agents (BMAs) reduce the incidence of skeletal-related events (SREs) and are recommended for breast cancer patients with bone metastasis. However, the risk factors for developing SREs,...

Date: 27 Sep 2014
Presenter: Ryota Tanaka
Resources: Abstract
Topics: Supportive Care, Breast Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...-breast-cancer-patients-with-bone-metastases

AimThis study evaluates the clinical course of breast cancer patients with bone metastases (BM) who developed pathological fractures (PF).MethodsThe study is based on data of the Basel Breast Cancer Database (Basel, Switzerland).

Date: 27 Sep 2014
Presenter: Marcus Vetter
Resources: Abstract
Topics: Supportive Care, Breast Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...-Trial-A-randomized-Phase-III-trial-in-NSCLC

AimErlotinib is approved for the treatment of patients with metastatic NSCLC following progression of chemotherapy as well for patients who harbour an EGFR mutation. Rash may limit exposure to drug and compromise efficacy.

Date: 27 Sep 2014
Presenter: Barbara Melosky
Resources: Abstract
Topics: Complications of Treatment, Supportive Care, Non-Small-Cell Lung Cancer, Metastatic